News for Vertex Pharmaceuticals Incorporated (0QZU.L)

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.

[url="]Vertex Pharmaceuticals Incorporated[/url] (Nasdaq: VRTX) and [url="]Ono Pharmaceutical Co., Ltd.[/url] (OTCMKTS: OPHLY) today announced an exclusive col

Vertex Pharmaceuticals (VRTX) and Ono Pharmaceutical (OPHLY) forge an exclusive agreement for povetacicept in Japan and South Korea. Ono will handle mar

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) American Diabetes Association (ADA) 85th Scientific Sessions Conference June 20, 2025 8:15 PM ETCompany...

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 2:40 PM ETCompany...

[url="]Vertex Pharmaceuticals Incorporated[/url] (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of lif

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bernstein 41st Annual Strategic Decisions Conference May 30, 2025 8:00 AM ETCompany ParticipantsReshma...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain. Click to read why VRTX is a Buy.

-Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, long-acting Factor XI (FXI) small inter

[url="]Vertex Pharmaceuticals Incorporated[/url] (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa,

Vertex Pharmaceuticals (VRTX) will participate in three major investor conferences in May and June 2025. Key executives, including CEO Dr. Reshma Kewalr

On CNBC's “Halftime Report Final Trades,” Brenda Vingiello, Chief Investment Officer of Sand Hill Global Advisors, picked Wynn Resorts, Limited WYNN as her ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best stocks to buy according to Jim Simons’ Renaissance Technologies. Even after his passing in 2024, billionaire investor and […]

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell […]

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX stock a Buy.